← Back to all trials
Recruiting
NCT06133972
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Conditions: Systemic Lupus Erythematosus
Sex: All
Ages: 12 Years – 100 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 550
Sponsor: Novartis Pharmaceuticals
Location: Pinnacle Research Group Llc Anniston Alabama
Summary
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Eligibility Criteria
Key Inclusion Criteria:
* Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants \
Source: ClinicalTrials.gov (NCT06133972). StuddyBuddy aggregates publicly available trial information.
